|By Marketwired .||
|February 11, 2013 08:01 AM EST||
LOS ANGELES, CA -- (Marketwire) -- 02/11/13 -- Small cap biopharmas that make for good long term investments are hard to find. Most small cap biopharmas burn a ton of cash while developing treatments for a variety of ailments and rare diseases.
Today, we focus on Pozen (NASDAQ: POZN) which we feel may present a good longer term speculative investment as well as a good trade with near term catalysts.
Pozen reminds us of another company we came across in 2011, Antares Pharma Inc., which produced an 80% gain in 14 months.
Antares is not a typical biotech that develops drugs to treat rare diseases such as the ones mentioned above. Rather, the company aims to take existing treatments and make them better via subcutaneous self-injections. When we first covered Antares, the price was around $2.20 a share. Within one year, the stock nearly tripled, hitting a 52 week high of $5.58, before settling back to the high $3 range, where it trades today.
Like Antares, Pozen takes existing drugs and seeks to make them safer and better -- more tolerable. Today, we will look at the management, pipeline, upcoming catalysts, partnership potential, and noteworthy financial items for Pozen.
One reason Pozen reminds us of Antares is because of the strong management with impressive backgrounds.
John R. Plachetka, Pharm.D., is President, Chief Executive Officer, and Chairman of the Board of Directors of Pozen. Prior to founding the company in 1996, Dr. Plachetka has held many high level positions in the pharmaceutical industry. Most notably, he had a nine-year career at Glaxo Inc. where Dr. Plachetka held various executive positions including Director of Cardiovascular Clinical Research and led the U.S. development program for Imitrex®, Trandate®, and a thromboxane antagonist.
Mr. Plachetka is the firm's biggest shareholder holding over two million shares. He is also responsible for bringing Liz Cermak on as the firm's Executive Vice President and Chief Commercial Officer. A former Worldwide Vice President for Johnson & Johnson, Liz has served in a variety of senior leadership roles across the pharmaceutical, consumer products, and health management businesses. She has over 25 years' experience in the healthcare industry.
The CEO's heavy ownership stake is one of the reasons why we believe the management team is extra focused with added incentives to perform well for its investors. The scenario arguably communicates a direct sense of personal accountability towards building shareholder value for investors in the company. The more that CEO is able to create shareholder value, the more he will ensure his own compensation and benefits.
The value of the management's approach has been proven with its success in gaining FDA approval of two self-invented products. One of these products is Treximet, developed with pharmaceutical giant GlaxoSmithKline in June 2003 for the acute treatment of migraine attacks in adults.
In what appears to be a very smart move, Pozen sold most of the future royalty and milestone payments covering Treximet sales in the United States to a financial investor for $75 million in November, 2011. On the surface, this move did not appear to carry much weight, but upon closer inspection we noticed that the company is piggybacking the product by retaining exclusive U.S. rights to develop and market a lower dose: sumatriptan and naproxen combination (MT400). This is the same combination used in Treximet. By making the move, the company raised tens of millions while keeping virtually the same product in development.
A pipeline chart later in this article shows the MT 400 drug in Phase III development. As a result of the Treximet decision, one year later the company remains shareholder friendly having achieved a hefty cash position while avoiding dilution.
As of the end of Q3, 2012, Pozen had approximately $92 million in cash and short term investments. In contrast, the dilution to raise cash was one annoyance we had with an otherwise capable management team at Antares. While it may ultimately be the best course of action for them moving forward, when they raised money last year, it left many investors feeling like it was unnecessary at the time.
Pozen plans on filing an NDA in April for its first PA product PA32540, which is a combination of 325 mg aspirin and 40 mg time-released omeprazole, better known as Prilosec, originally created by AstraZeneca.
From the company's website, we read;
"Pozen's active PA product portfolio is focused on designing cost-effective, integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal (GI) damage. The PA product portfolio has the potential to benefit millions of Americans who use daily aspirin to treat cardiovascular disease, osteoarthritis, and other diseases."
PA32540 is designed to be a GI-safer form of aspirin to be administered orally once a day, at a cost of 1 dollar per day. PA32540 prevents secondary cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
Last week, the company announced the combined results of two Phase III studies of PA32540:
"According to the studies, in the post-hoc analysis of subjects with a history of transient ischemic attack (TIA) or stroke, long-term (6 months) treatment with PA32540, compared to EC-ASA (325 mg), was associated with a significantly reduced rate of endoscopic gastroduodenal ulcers (2.0% vs. 12.4% respectively; p=0.005), and study discontinuation due to adverse pre-specified upper GI events (0% vs. 8.0% respectively; p=0.006). The incidence of adjudicated major adverse cardiac events was similar for PA32540 (2.9%) and EC-ASA (325 mg) (4.4%)."
Mark J. Alberts, MD, UT Southwestern Medical Center, Dallas, Texas remarked:
"Discontinuation of aspirin therapy is often due to the adverse GI effects of aspirin. In these pivotal studies, PA32540 was associated with a significantly lower rate of treatment discontinuation than aspirin alone. Patient adherence to aspirin therapy saves lives, as aspirin discontinuation increases the likelihood of potential adverse cardiovascular and cerebrovascular events."
In an article written by analyst Jason Napodano, he notes:
"Amazon.com sells a 500 tablet bottle of 325 mg aspirin for $11.00, or 2.2 cents per day. One can also buy 42 20 mg tablets of OTC Prilosec (omeprazole) for $23.95, or around 57 cents per pill. To re-create Pozen's PA-325/40, a patient would spend approximately $1.16 per day (taking two Prilosec pills plus an aspirin)."
The above clearly demonstrates why it would be beneficial to choose Pozen's drug over taking aspirin and Prilosec separately -- it would cost less at 1 dollar a day for a patient to buy PA32540 versus buying both drugs separately for $1.16. Additionally, PA32540 is time released and contains a dose specific solution in one pill where patients need not to worry about mixing both medications to get the desired result.
The above referenced article goes on further to note that the PA platform might be worth as much as $400M in sales per year globally, with the company receiving at least a $30M upfront payment from any potential partner. With an NDA filing expected in April the company's desire to secure a partner before the filing, we would expect that Pozen's stock price may see an increase in the short term.
A partnership could spark the stock price, depending on the details of the transaction. Generally, it shows that the development of a drug will be expedited and the potential is going to be greater because of more power and resources behind it. Last year, Sunesis Pharmaceuticals gained 15% on a day when it announced a partnership with Royalty Pharma. Royalty Pharma agreed to pay Sunesis $25 million if the company is successful developing its lead product candidate Vosaroxin, which is an anticancer quinolone derivative class of compounds that have never used to attempt to treat cancer. In the time since, Sunesis has seen a stock price increase of well over 100% from $2.87 to $6.18.
Pozen is already partnered with such pharma giants as GlaxoSmithKline, Johnson & Johnson, and AstraZeneca. This tells us Pozen's management has experience with gaining partnership deals with large pharmas.
The graphic at Pozen's website shows the rest of Pozen's marketed and pipelined solutions. It is worth noting that the company has other solutions that will also see NDA filings within the next year.
Pozen was profitable for the first two quarters of 2012, before showing a loss in the last two quarters of the same year. This was in part due to less than expected sales from Vimovo, which is partnered with AstraZeneca. AstraZenca may have priced Vimovo too high at $4 a day, causing the drug to lose market acceptance. However as Jason Napodano reported in his article, AstraZenca may become more aggressive in its price point for the drug. Furthermore, AstraZeneca has filed Vimovo in 80 countries, receiving approval in 60 countries, and is currently launched in 40 countries. This leaves about 40 countries left for approval and roll out of the drug, which will equate to more revenue for Pozen moving forward.
Share Statistics Avg Vol (3 month): 96,155 Avg Vol (10 day): 137,488 Shares Outstanding: 30.31M Float: 24.52M % Held by Insiders: 11.15% % Held by Institutions: 66.20% Shares Short (as of Jan 15, 2013): 1.70M Short Ratio (as of Jan 15, 2013): 17.80 Short % of Float (as of Jan 15, 2013): 6.40% Shares Short (prior month)(3): 1.71M
The stock price and volume have been increasing steadily over the last two weeks or so. With nearly 6.4% of the float held short, Pozen makes for a decent short squeeze candidate. Institutional ownership is high, especially for a stock selling in the high $5 range like Pozen.
With a market cap of $173.06M, we believe that Pozen is undervalued by about $100M when considering the market opportunity for its PA platform, 40 more countries to roll out Vimovo, and the likeliness of a partnership for PA32540 which as already mentioned, should net at least a $30M upfront payment.
From the chart we can observe that the stock appears to be reversing the extended down trend it has seen since May of last year. It appears to me that catalyst traders and investors are accumulating the stock. With the NDA filing for PA32540 expected in April, and the likeliness of the company gaining a significant partnership with the drug before then, a short term price appreciation to the $6.50 range looks to be in short order.
Disclosure: Author Scott Matusow is Long POZN.
The full version of this report complete technical analysis charts can be found here:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
Media Contacts Only:
e-mail: Email Contact
- The Odd Couple: Marrying Agile and Waterfall
- Fanning the Flames of Agile
- April and May 2014 Server and StorageIO Update newsletter
- Big Data Expo 2014 Silicon Valley Call for Papers Now Open
- WSO2 Introduces Industry’s First Enterprise Identity Bus With the Launch of WSO2 Identity Server 5.0
- The Butterfly Effect Within IT
- Jim Miller at ImageWare Systems, George Romas at HP, Jody Ross at AMAG, + March Networks and StrikeForce Featured in SecuritySolutionsWatch.com Interviews
- Setting the Bar for Agile Architecture
- The Agile PMO
- Mobility News Weekly – Week of June 1, 2014
- Cloudera Strengthens Hadoop Security with Acquisition of Gazzang: Builds on additional community efforts to deliver end-to-end security offering
- Ukraine Has Potential in Midst of Chaos
- .CLUB Domain Name Extension Now Available for General Registration
- AMAG, HP, ImageWare Systems, March Networks and StrikeForce Discuss Security Solutions in SecuritySolutionsWatch.com Interviews
- The Odd Couple: Marrying Agile and Waterfall
- Flexera Software’s InstallShield 2014 Release Introduces New Support of Cloud and Virtualised Installations, High-DPI Displays and Touch Devices, and Agile Development
- FlexNet Manager Suite Wins CODiE Award for Best Asset Management Solution - 4th CODiE Award for Flexera Software
- Learn How You Can Easily Extend Your Infrastructure with Microsoft Azure
- Fanning the Flames of Agile
- Flexiant Acquires Besol’s Tapp Multi-Cloud Management Technology and Business
- Big Data, Cloud and Mobile - Converging Technology Trends
- Ten Answers Regarding Mobile App Testing
- April and May 2014 Server and StorageIO Update newsletter
- Windows Least Privilege Management and Beyond
- Google Maps and ASP.NET
- Converting VB6 to VB.NET, Part I
- How to Write High-Performance C# Code
- Where Are RIA Technologies Headed in 2008?
- Crystal Reports XI & How It Has Changed
- Creating Controls for.NET Compact Framework in Visual Studio 2005
- Programmatically Posting Data to ASP .NET Web Applications
- Implementing Tab Navigation with ASP.NET 2.0
- AJAX World RIA Conference & Expo Kicks Off in New York City
- The Top 250 Players in the Cloud Computing Ecosystem
- i-Technology Viewpoint: "SOA Sucks"
- .NET Archives: Getting Reacquainted with the Father of C#